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Background: A liquisolid technique has been reported to be a new approach to improve the 
release of poorly water-soluble drugs for oral administration. However, an apparent limitation 
of this technique is the formulation of a high dose because a large amount of liquid vehicle is 
needed, which finally results in a low-dose liquisolid formulation. Silica as an absorbent has 
been used extensively in liquisolid formulations. Although nanoparticle silica can be prepared 
and used to improve liquid adsorption capacity, loading a high dose of drug into a liquisolid 
is still a challenge. With the aim of improving adsorption capacity and accordingly achieving 
high drug loading, ordered mesoporous silica with a high surface area and narrow pore size 
distribution was synthesized and used in a liquisolid formulation.
Methods: Ordered mesoporous silica was synthesized and its particle size and morphology were 
tailored by controlling the concentration of cetyltrimethyl ammonium bromide. The ordered 
mesoporous silica synthesized was characterized by transmission electron microscopy, scanning 
electron microscopy, Fourier transform infrared spectroscopy, small-angle x-ray   diffraction, 
wide angle x-ray diffraction, and nitrogen adsorption-desorption measurements. The liquid 
adsorption capacity of ordered mesoporous silica was subsequently compared with that of 
conventional silica materials using PEG400 as the model liquid. Carbamazepine was chosen 
as a model drug to prepare the liquisolid formulation, with ordered mesoporous silica as the 
adsorbent material. The preparation was evaluated and compared with commercially available 
fast-release carbamazepine tablets in vitro and in vivo.
Results: Characterization of the ordered mesoporous silica synthesized in this study indicated 
a huge Brunauer–Emmett–Teller surface area (1030 m2/g), an ordered mesoporous structure 
with a pore size of 2.8 nm, and high adsorption capacity for liquid compared with conventional 
silica. Compared with fast-release commercial carbamazepine tablets, drug release from the 
liquisolid capsules was greatly improved, and the bioavailability of the liquisolid preparation 
was enhanced by 182.7%.
Conclusion: Ordered mesoporous silica is a potentially attractive adsorbent which may lead 
to a new approach for development of liquisolid products.
Keywords: ordered mesoporous silica, poorly water-soluble drug, carbamazepine, liquisolid, 
bioavailability
Introduction
In recent years, the liquisolid technique has been reported as a new approach to improve 
the rate of release of poorly water-soluble drugs intended for oral administration.1–7 
With this technique, liquid formulations, such as solutions or suspensions of water-
insoluble solid drugs in nonvolatile liquid vehicles, can be converted into free-flowing 
and readily compressible powders by blending with selected powder excipients, 
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ie, carrier and coating materials. The advantages of this 
technique include process simplicity, low cost, and   controlled 
drug release.8,9 However, an apparent limitation of this 
technique is the formulation of high doses because a large 
amount of liquid vehicle is needed, and accordingly, a large 
amount of carrier and coating materials needs to be used, 
which results in low-dose drug formulations.
Silica powder has been widely used as a coating material 
in liquisolid formulations for liquid adsorption due to its large 
specific surface area, and nontoxic and inert characteristics.10 
Although nanoparticle formulations of silica, such as 
Aerosil®200 and HDK®N20P with a surface area of 200 m²/g 
were prepared and used to improve liquid adsorption 
capacity, loading high doses of drugs in a liquisolid is still 
a challenge.
First reported by Mobil scientists,11,12 mesoporous silica 
has attracted considerable attention as a molecular sieve due 
to its inherent properties, such as a large pore volume and 
surface area, and a tunable narrow pore size distribution.13,14 
These properties suggest that mesoporous silica may have a 
higher liquid adsorption capacity when used in liquisolid for-
mulations as compared with conventional silica. To confirm 
this assumption, ordered mesoporous silica was synthesized 
in the present study using a surfactant-directing method. 
In previous research, many methods had been reported for 
control of the morphology and particle size of mesoporous 
silica by varying the parameters of synthesis, including 
temperature,15 pH value,16 cosolvent,17 and   cosurfactant.18 
In the present study, particle size and morphology of 
ordered mesoporous silica was explored by controlling the 
concentration of surfactant. The ordered mesoporous silica 
synthesized was characterized by small-angle x-ray diffrac-
tion, wide angle x-ray diffraction, scanning electron micros-
copy, transmission electron microscopy, Fourier transform 
infrared spectroscopy, and nitrogen adsorption-desorption 
measurements. The liquid adsorption capacity of ordered 
mesoporous silica was subsequently compared with that 
of conventional silica materials using PEG400 as a model   
liquid.
Carbamazepine (5H-dibenzazepine-5-carboxamide) 
is classified as a class II drug (low solubility and high 
permeability) according to the biopharmaceutic classification 
system.19 This high-dose drug ($100 mg) is also known to 
have four anhydrous polymorphs, and these polymorphs 
may affect drug release and bioavailability.20,21 Therefore, 
carbamazepine was chosen as a model drug to prepare 
a liquisolid formulation with ordered mesoporous silica 
as the adsorbent material. The preparation was evaluated 
and compared with commercially available fast-release 
carbamazepine tablets in vitro and in vivo.
Materials and methods
Materials
Carbamazepine was purchased from Suzhou Hengyi 
Pharmaceuticals Co, Ltd (Jiangsu, China). Commercially 
available fast-release carbamazepine 100 mg tablets 
were purchased from Guangdong Huanan Pharmacy Ltd 
(Guangdong, China). Starch 1500, microcrystalline cellulose 
(Vivapur 12), and HDK®N20P silica (Wacker, Munich, 
Germany) were kindly donated by Jiefu Trade Co, Ltd 
(Guangzhou, China). Microsilica was obtained from Huzhou 
Zhanwang Pharmaceutical Co, Ltd (Zhejiang, China). 
Standard silica (99.999%) was obtained from Shanghai 
Reagent Factory (Shanghai, China). PEG 400 was purchased 
from Sigma-Aldrich (Hong Kong, China). Cetyltrimethyl 
ammonium bromide (CTAB), tetraethoxysilane, and ammonia 
were obtained from Fuchen Chemicals Reagent Factory 
(Tianjin, China). High-pressure liquid chromatography 
(HPLC)-grade acetonitrile was obtained from Fisher 
Scientific (Beijing, China). Other chemicals were of reagent 
grade and used without further purification.
Ordered mesoporous silica synthesis
Ordered mesoporous silica was synthesized in alkaline 
media using modified literature recipes.22 Typically, 5 g of 
CTAB was dissolved in 520 mL of 15% (w/w) ammonia at 
60°C under constant stirring at 200 rpm for 0.5 hours. Then 
20 mL of tetraethoxysilane was added dropwise into the 
solution under continuous stirring for 2 hours. After aging in 
a sealed container at 60°C for 24 hours without stirring, the 
mixture was filtered to recover the solid. The solid product 
was washed with water until the filtrate was neutral and 
then rinsed twice with alcohol before being dried overnight 
at 80°C. Calcination of the solid product was carried out by 
slowly increasing the temperature from room temperature to 
550°C within 4 hours and maintaining at 550°C for another 
6 hours. At last, a pure white and feathery powder, ordered 
mesoporous silica, was obtained.
The synthesis of ordered mesoporous silica consists 
of a series of hydrolysis and condensation reactions of an 
alkoxide at the surface of CTAB micelles. The   condensation 
reaction proceeds either via alcohol condensation or water 
condensation. The total reaction can be summarized as 
follows:
  nSi(OC2H5) + 2nH2O = nSiO2 + 4nC2H5OH
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
200
Chen et alInternational Journal of Nanomedicine 2012:7
To control the particle size and shape of ordered 
mesoporous silica, the same synthesis process described above 
was carried out by varying the concentration of CTAB in a 
range of 0.5%–3.0% (w/w). The yield of ordered   mesoporous 
silica was calculated according to the following formula:
  Y (yield) = WOMS/(WTEOS × 28.4%) × 100%
where WOMS and WTEOS are the weight of ordered mesoporous 
silica collected after calcination and tetraethoxysilane, 
respectively.
Characterization of ordered mesoporous 
silica
Scanning electron microscopy measurements were carried out 
with a JSM-6330F microscope (JEOL, Tokyo, Japan). Samples 
were deposited on the surface of a silicon wafer by dropping a 
suspension of samples in ethanol which was presonicated for 
5 minutes, and then sputter-coated for two cycles with gold. 
Transmission electron microscopy was performed by a low-
exposure technique using a JEOL 2010 electron microscope 
with analySIS 5.0 software (Olympus, Münster, Germany) 
to reduce the influence of beam damage and sample drift. 
Samples for transmission electron microscopy measurements 
were prepared by dipping a carbon-coated copper grid into a 
suspension of sample in ethanol, which was presonicated for 
5 minutes. The pore size and pore wall thickness were mea-
sured by analySIS 5.0 software, which can directly show the 
results after selecting the object of measurement.
Nitrogen adsorption-desorption isotherms were measured 
at −196°C by ASAP 2020C (Micromeritics, Norcross, GA). 
Prior to analysis, the samples were degassed in a vacuum at 
300°C for 3 hours. Pore volume was determined from the 
adsorption branch of nitrogen adsorption-desorption iso-
therm curve at a relative nitrogen pressure P/P0 = 0.975 signal 
point. Pore diameter was calculated from the adsorption 
branch of the isotherms using the Barrett–Joyner–Halenda 
method, and specific surface area was calculated using the 
multiple-point Brunauer–Emmett–Teller method.
Fourier transform infrared spectra were obtained using a 
Fourier transform infrared spectrometer (Bruker, Germany) 
to scan over a spectral region of 400–4000 cm−1 on a thinly 
sliced sample compressed from the dry mixture of ordered 
mesoporous silica and KBr.
Small-angle and wide-angle x-ray diffraction patterns 
of ordered mesoporous silica were analyzed on a D/MAX 
2200VPC diffractometer (Rigaku, Tokyo, Japan) using 
CuKα radiation with 2θ in the range of 0.6°–6° and 10°–40°, 
respectively.
Evaluation of adsorption capacity  
with liquid
PEG400 was used as a model liquid to evaluate the 
adsorption capacity of the silicas. Firstly, conventional 
silicas (HDK®N20P silica and Microsilica) and ordered 
mesoporous silica were dried at 150°C for 2 hours in order 
to remove any residual moisture. Then 1.0 g of each silica 
sample was mixed with an adequate amount of PEG400. 
The mixture was sealed in a container for one hour to 
reach an adsorption equilibrium. Afterwards, the mixture 
was spread on a preweighed filter paper and subsequently 
sealed in a container overnight to remove the overloading 
of liquid from silicas by adsorbing any free liquid onto 
filter paper. Finally, the solid mixture was carefully 
removed and the filter paper was weighed accurately again. 
The adsorption capacity was calculated according to the 
following formula:
  A (adsorption capacity) = [Wl
 − (Wf1 − Wf0)]/Wm
where Wl and Wm are the weight of liquid and silica material, 
respectively; Wf0 and Wf1 represent, respectively, the   original 
weight and final weight after removing materials of the filter 
paper.
Angle of repose test
In order to determine the appropriate ratio of carrier and 
coating material in the liquisolid system, the angle of repose 
was measured using a BT-1000 powder characteristics tester 
(BT, Dandong, China), which can directly read out the angle 
of repose of a sample without calculation.
Preparation of liquisolid capsules
Two liquisolid formulations, denoted as F1 and F2, were 
prepared using carbamazepine as the model drug and 
ordered mesoporous silica as follows. For F1, about 3 g 
of carbamazepine was dissolved in 40 mL of PEG400 to 
  prepare the liquid medication. Then 15 g of a binary mixture 
of starch 1500 as the carrier and ordered mesoporous silica 
as the coating material at the ratio of 2:1 (w/w), which was 
determined by the results of the angle of repose, was added 
to the liquid medication under continuous mixing to form 
a liquisolid   system. Afterwards, 3 g of 10% starch slurry 
was added into the liquisolid system to obtain a wet powder 
mixture for granulation. The granules were produced through 
a 16 mesh sieve and dried in an oven at 40°C overnight. 
Finally, the dried granules were encapsulated into hard shell 
gelatin capsules.
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To investigate the influence of the carrier on drug release, 
another formulation, F2, was prepared using microcrystalline 
cellulose as the carrier instead of starch 1500 following the 
same preparing steps described above.
In addition, conventional silica, N20P, was used as a 
coating material to mix with starch 1500 as the carrier to 
prepare carbamazepine liquisolid capsules following the 
same preparing steps. However, due to the poor adsorption 
capacity of N20P, in order to obtain flowability similar to 
that of F1 granules, 30 g of a binary mixture of starch 1500 
and N20P at a ratio of 2:1 (w/w) was used to load the same 
amount of carbamazepine liquid. This control formulation 
was denoted as F3.
In vitro dissolution test
The dissolution test was carried out using a USP II paddle 
method (75 rpm, 900 mL of simulated gastric fluid as dis-
solution medium at 37°C) with a ZRS-8G dissolution tester 
(TDTF, Tianjin, China). A sample equivalent to 100 mg of 
carbamazepine was added to each vessel. At predetermined 
time intervals, 5 mL of dissolution medium was withdrawn, 
filtered through a 0.22 µm Millipore filter, and assayed by 
ultraviolet absorption at a wavelength of 284 nm. An equal 
amount of fresh medium was added to the vessel after each 
sample was drawn for compensation. Each dissolution test 
was performed in triplicate.
Animal experiments
All animal experimental procedures were approved by 
the animal ethics committee of Sun Yat-sen University in 
accordance with National Institute of Health and Nutrition 
Guidelines for the Care and Use of Laboratory Animals. 
Six healthy 1.5–2.0 year old female beagle dogs weighing 
14–15 kg were used in a two-treatment, two-period, two-
sequence crossover design. Prior to each study, the dogs 
were fasted for 14–16 hours but allowed to drink water ad 
libitum. On each occasion, the dogs received the following 
oral formulations and 40 mL of water: one commercially 
available fast-release carbamazepine 100 mg tablet, or four 
liquisolid capsules (F1) equivalent to a dose of 100 mg 
carbamazepine. A washout period of at least two weeks was 
allowed between treatments.
Prior to drug administration and at 10, 20, 30, 45, 60, 75, 
90, 120, 180, 240, 300, and 480 minutes after dosing, 4 mL 
blood samples were taken into heparinized tubes at each 
time point through the cephalic vein of the hind leg. Plasma 
was separated by centrifugation (3000 rpm, 15 minutes) and 
stored at −20°C prior to analysis.
Analysis of plasma carbamazepine 
concentration
Carbamazepine was assayed using an HPLC method, 
which was validated following international guidelines. 
A 500 µL plasma sample was mixed with 20 µL of methanol 
containing an internal standard (pentobarbital, 100 µg/mL) 
and vortexed for 30 seconds. The sample was then mixed 
with 2 mL of acetoacetate as the extraction solvent and 
  vortexed for 3   minutes, followed by centrifugation at 10,000 
rpm for 3 minutes to separate the layers. The supernatant 
was collected into clean centrifuge tubes by aspiration and 
evaporated under vacuum at room temperature for 2 hours. 
The evaporated sample was redissolved in 150 µL of mobile 
phase, then 50 µL of this test sample was injected for HPLC 
analysis.
The HPLC analysis was carried out on a Waters model 
1525 pump equipped with a 2487 ultraviolet detector, a 717 
autosample system, and Empower software. Carbamazepine 
separation was completed on a Symmetry® C 18 column 
(4.6 × 250 mm, 5 µm) with a guard column (4.6 × 12.5 mm, 
5 µm) using a mobile phase consisting of acetonitrile and 
water (40:60, v/v) at a flow rate of 1.0 mL/minute. The 
detection wavelength was set at 230 nm. The column 
working temperature was kept at 40°C, and the injection 
volume was 50 µL. Under these conditions, carbamazepine 
and pentobarbital eluted at approximately 8 minutes and 
9 minutes, respectively. A linear standard curve was generated 
(r2 . 0.99) over the examined carbamazepine concentration 
range of 0.05–3.0 µg/mL. With a limit of quantitation of 
0.05 µg/mL, the accuracy of the assay was 90%–110%, and 
the interday and intraday precisions in terms of coefficients of 
variation were all less than 10%. Carbamazepine recoveries 
for three different concentrations (0.1, 1.0, and 3.0 µg/mL) 
were 99.1% ± 1.6%, 100.8% ± 4.0%, and 98.0% ± 2.2%, 
respectively.
Pharmacokinetic and statistical analyses
The peak plasma concentration (Cmax) and the time to 
reach the peak plasma concentration (Tmax) were obtained 
directly from the individual plasma concentration-time 
data. The area under the plasma concentration-time curve 
(AUC0–∞) was calculated by the trapezoidal rule from time 
0 to infinity. The elimination constant (Ke) was estimated 
from the elimination segment of the curve, as the slope of 
logarithm concentration-time plot, while the half-time (t1/2) 
was calculated as 0.693/Ke. The relative bioavailability 
was calculated as [(AUCtest × Dref)/(AUCref × Dtest)] × 100, 
where D is the dose, and “test” and “ref” correspond to the 
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liquisolid formulation and commercial tablet, respectively. 
For statistical evaluation, analysis of variance was used 
to assess the significance of the difference between the 
pharmacokinetic parameters obtained.
Results and discussion
Synthesis of ordered mesoporous silica
In the present study, ordered mesoporous silica of different 
morphology and particle size was synthesized by varying 
the concentration of the surfactant, CTAB. As shown in 
  Figure 1, approximately spherical, rod-like, and curled 
  rod-like mesoporous silicas were obtained. All particles were 
well monodispersed with a smooth surface, even after calci-
nation at 550°C for 6 hours. With increasing concentrations 
of CTAB, it was noticed that the ordered mesoporous silica 
particles elongated in one direction, resulting in an increase 
in particle size.
On the other hand, it was noticed that lowering the CTAB 
concentration reduced the yield of ordered   mesoporous 
silica remarkably. As shown in Table 1, the yield of ordered 
mesoporous silica with 0.5% CTAB was less than 50%, 
while the yield of ordered mesoporous silica with 0.8% 
CTAB was more than 80%. This may be due to CTAB,   
a structure-directing template, promoting the hydrolysis of an 
alkoxide. During hydrolysis and condensation of an alkoxide, 
bromide ions of CTAB are exchanged for silicate anions at 
the CTAB micelle surface,23,24 which leads to rapid hydrolysis 
of the alkoxide, resulting in complete formation of ordered 
mesoporous silica. However, in the case of 0.5% CTAB, too 
little CTAB may not be able to speed up the hydrolysis of 
alkoxide, resulting in incomplete formation and a low yield 
of ordered mesoporous silica.
In addition, the adsorption capacity of ordered   mesoporous 
silica synthesized with different concentrations of CTAB 
is compared in Table 2. Only ordered mesoporous silica 
  synthesized with 0.5% CTAB showed slightly higher 
adsorption capacity than the other formulations. However, 
the P values were all .0.05, indicating that the differences in 
adsorption capacity were not statistically significant between 
ordered mesoporous silica synthesized with 0.5% CTAB and 
the other formulations.
As a result, when the concentration of CTAB was in 
the range of 0.8%–3.0%, the adsorption capacity and yield 
of ordered mesoporous silica did not show significant 
  differences. However, it has been reported that CTAB has 
marked cytotoxicity.25 Therefore, the formulation with the 
lowest concentration of CTAB, ie, 0.8%, was selected for 
further study.
Characterization of ordered mesoporous 
silica
The scanning electron images in Figure 1B show that the 
ordered mesoporous silica particles were rod-like in shape 
with a hexagonal cross-section (pointed to by arrows in 
Figure 1B). The transmission electron microscopic image of 
ordered mesoporous silica (Figure 1F) shows bright and dark 
areas which correspond to pores and silica walls, respectively. 
This confirms the hexagonal structure of ordered mesoporous 
AB C
DE F
Figure 1 Scanning electron microscopic images of ordered mesoporous silica synthesized with different concentrations of cetyltrimethyl ammonium bromide (w/w). 
(A) 0.5%, (B) 0.8%, (C) 1.0%, (D) 1.5%, and (E) 3%; and (F) transmission electron microscopic image of ordered mesoporous silica with 0.8% cetyltrimethyl ammonium 
bromide.
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silica and further illustrates well-ordered mesopores with an 
average pore size of about 2.8 nm, as measured by analySIS 
5.0 software.
In order to obtain more precise information about 
the structure of mesoporous silica, nitrogen adsorption-
desorption measurements were performed. Figure 2 shows 
the nitrogen adsorption-desorption isotherms for ordered 
mesoporous silica which demonstrate a type IV isotherm with 
a typical capillary condensation step in the mesopores at a 
relative nitrogen pressure p/po ranging from 0.25 to 0.4. This 
indicates that the samples possessed typical mesostructural 
ordering and a relatively uniform pore size distribution.26 The 
corresponding pore size distribution (Figure 3) calculated 
from the adsorption branch of the isotherms showed a narrow 
distribution of pore size in the range of 2.0–3.3 nm. The 
mean Brunauer–Emmett–Teller surface area, pore volume, 
and pore size were calculated as 1030 m2/g, 0.81 cm3/g, 
and 2.8 nm, respectively. These findings imply a high 
adsorption capacity for ordered mesoporous silica. Further, 
the calculated mean pore size was consistent with the value 
measured on transmission electron microscopy images. 
However, the nitrogen adsorption-desorption isotherms 
for the two conventional silicas, ie, Microsilica and N20P, 
were quite different from that for ordered mesoporous silica 
(Figure 2). The isotherms for the conventional silicas are 
type III according to the International Union of Pure and 
Applied Chemistry classification, which is characteristic 
of nonporous or macroporous solids.27 Their corresponding 
pore size distribution also showed the absence of peaks in 
the range of 2–50 nm. The Brunauer–Emmett–Teller surface 
areas of Microsilica and N20P were 78 m2/g and 194 m2/g, 
respectively.
The small-angle x-ray diffraction pattern of ordered 
mesoporous silica (Figure 4A) showed three well resolved 
peaks which were indexed as (100), (110), and (200) 
reflections associating with P6 mm hexagonal symmetry, 
and this   suggests a good long-range order of pores in 
ordered mesoporous silica. Based on the formula a0 = (2/ 3) 
d100
28, the lattice parameter a0 was calculated as 4.32 nm. 
Considering the pore wall thickness of 1–2 nm, as measured 
in Figure 1F, the pore size of ordered mesoporous silica 
was calculated as 2–3 nm by subtracting the pore wall 
thickness from a0, and this was in agreement with the above 
measurements.
The wide angle x-ray diffraction pattern (Figure 4B) 
confirmed that the ordered mesoporous silica was amorphous 
silicon dioxide, on account of a broad peak ranging from 2θ 
of 15° to 30°, and this result is consistent with the published 
literature.29
CTAB has been used in research as a mesoporous 
template during ordered mesoporous silica synthesis and 
removed by post-synthesis calcination. However, CTAB was 
reported to have marked cytotoxicity,25 and to ensure CTAB 
was completely removed by calcination, Fourier transform 
infrared spectroscopy detection was carried out. As shown in 
Figure 5, the spectrum of CTAB showed two intense peaks 
at 2800–3200 cm−1, which were assigned to the asymmetric 
(2918 cm−1) and symmetric (2849 cm−1) stretching vibra-
tions of CCH2 in the methylene chains.30 These peaks 
were observed in as-synthesized ordered mesoporous silica 
but absent in calcined ordered mesoporous silica, indicating 
that CTAB was completely removed by calcination. In the 
region of 400–1800 cm−1, characteristic peaks of silica were 
observed in as-synthesized ordered mesoporous silica and 
calcined ordered mesoporous silica, as well as in standard 
silica, indicating ordered mesoporous silica was pure silica 
and its chemical structure was intact, even after calcination 
at 550°C for 6 hours.
Table 1 Particle size and yield of OMS synthesized with different concentrations of CTAB
CTAB Concentration (%, w/w) 0.5 0.8 1.0 1.5 3.0
Particle shape Near spheres Rod-like Rod-like Rod-like Cured rod-like
Mean particle size (nm) D: 280 D: 300 
L : 400
D: 260 
L: 510
D: 280 
L: 850
D: 200 
L: 1000
Yield (%) 42.3 89.4 90.5 91.3 90.2
Abbreviations: D, diameter; L, length; CTAB, cetyltrimethyl ammonium bromide; OMS, ordered mesoporous silica.
Table 2 Adsorption capacity of OMS synthesized with different concentrations of CTAB (n = 3)
CTAB Concentration (%, w/w) 0.5 0.8 1.0 1.5 3.0
Adsorption capacity (g/g) 7.04 ± 0.22 6.87 ± 0.30 6.75 ± 0.30 6.56 ± 0.24 6.60 ± 0.27
P value* 0.36 0.33 0.10 0.15
Note: *P values were calculated between OMS with 0.5% CTAB and the other OMS formulations. 
Abbreviations: CTAB, cetyltrimethyl ammonium bromide; OMS, ordered mesoporous silica.
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Adsorption capacity
The above characterization results indicate that the 
  synthesized ordered mesoporous silica was quite different 
from conventional silicas with regard to large pore volume, 
a huge surface area, and ordered mesoporous structure. These 
properties implied that ordered mesoporous silica might be 
an excellent adsorbent. Therefore, the adsorption capacity of 
ordered mesoporous silica was evaluated in comparison with 
two conventional silicas, ie, Microsilica with a surface area 
of 78 m2/g and N20P with a surface area of 194 m2/g.
PEG400 has been extensively used in liquisolids as a 
hydrophilic liquid vehicle due to its nontoxic and nonvolatile 
properties and excellent dissolving capacity. For liquisolid 
formulations, poorly water-soluble drugs are firstly dissolved 
in hydrophilic fluids, and then adsorbed by coating materials, 
so the drug-loading capacity of the liquisolid formulation can 
be determined by the amount of adsorbing liquid PEG400 
vehicle.
The measured adsorption capacity of various silicas is 
compared in Figure 6, which clearly indicates the order of 
ordered mesoporous silica . N20P . Microsilica. Ordered 
mesoporous silica with a surface area of 1030 m2/g showed 
an adsorption capacity of 6.9 g/g, while the adsorption 
capacity of N20P and Microsilica was 3.9 g/g and 2.6 g/g, 
respectively. The results indicated that the adsorption capac-
ity was directly related to the surface area of the adsorbent. 
In addition, the mesoporous structure of ordered mesoporous 
silica not only contributed to a significantly larger surface 
area but also generated strong capillary forces to pull liquid 
into the pores.31–33 Therefore, ordered mesoporous silica can 
hold a larger amount of PEG400 than conventional silica. 
The adsorption capacity results suggested that the drug liquid 
loading might be doubled in a liquisolid with ordered mes-
oporous silica as compared with conventional silicas.
Angle of repose of liquisolid granules
In the preliminary study, it was noted that flowability of the 
liquisolid granules was influenced by the ratio of carrier to 
ordered mesoporous silica. Starch 1500 was chosen as a 
carrier to mix with the ordered mesoporous silica at various 
ratios (4:1, 2:1, and 1:1, w/w) in order to obtain free-flowing 
liquisolid granules. The angle of repose of the granules indi-
cated that the granules with carrier and ordered mesoporous 
silica at a ratio of 2:1 (w/w) had the best flowability (Table 3). 
When the ratio was 1:1 (w/w), the granules broke easily into 
a fine powder, resulting in poor flow. When the ratio was 
4:1 (w/w), the granules adhered together due to insufficient 
coating material to solidify the liquid. Therefore, a binary 
mixture of starch 1500 as the carrier and ordered mesoporous 
silica as the coating material at the ratio of 2:1 (w/w) was 
selected to form liquisolid system.
Carbamazepine in liquisolid characterized 
by x-ray diffraction
Carbamazepine has been found to exist in four   different 
anhydrous crystal polymorphs that may influence its 
  dissolution rate and bioavailability. Further, precipitation 
of carbamazepine may occur in a liquisolid formulation. 
Therefore, it is essential to investigate the physical state of 
carbamazepine in a liquisolid formulation. Figure 7 shows the 
x-ray diffraction patterns for pure carbamazepine, liquisolid 
formulations F1 (starch 1500 as carrier), F2 (microcrystalline 
cellulose as carrier), and the corresponding physical mixtures. 
Pure   carbamazepine was clearly present in a crystalline state 
because sharp distinct peaks were observed at 2θ diffraction 
angles of 13.10°, 15.31°, 19.50°, and 24.94° (Figure 7A). 
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These characteristic carbamazepine peaks were also observed 
in physical mixtures of F1 and F2 (  Figure 7B and D), 
  demonstrating that the crystalline   structure of   carbamazepine 
was retained during physical mixing. However, these peaks 
characteristic of carbamazepine were absent in liquisolid 
formulations of F1 and F2 (Figure 7C and E), indicat-
ing that carbamazepine was almost completely converted 
from a crystalline to an amorphous or solubilized form by 
the liquisolid technique. These results are in agreement with 
the published literature.6,34,35 In addition, it was noted that the 
peaks characteristic of carbamazepine were also absent in the 
ordered mesoporous silica containing carbamazepine liquid 
at the concentration used (Figure 7F), indicating that ordered 
mesoporous silica plays a key role in the amorphous or solu-
bilized form of carbamazepine in a liquisolid formulation. 
This amorphous or solubilized form of carbamazepine in the 
liquisolid formulation may also contribute to an improvement 
in the dissolution rate.
In vitro dissolution test
A dissolution study was performed with the aim of investigating 
the release behavior of carbamazepine from liquisolid capsules 
of F1 (starch 1500/ordered mesoporous silica), liquisolid cap-
sules of F2 (microcrystalline cellulose/ordered mesoporous 
silica), F3 (starch 1500/N20P), carbamazepine powder, and 
commercially available fast-release carbamazepine tablets. The 
dissolution profiles in Figure 8 appear to show that liquisolid 
formulation F1 generated the fastest dissolution rate. After 
30 minutes, 86.7% of carbamazepine was already released from 
F1, while only 71.7%, 69.0%, and 13.6% of carbamazepine 
was dissolved from F3, the commercial tablet, and the carbam-
azepine powder, respectively. The fast release of drug from 
liquisolid F1 was very likely due to the hydrophilic character 
of starch and ordered mesoporous silica, the amorphous or 
solubilized form of carbamazepine in liquisolid formulation, 
and the huge surface area of ordered mesoporous silica, leading 
to a large contact area with the dissolution medium.
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It is important to note that the release of carbamazepine 
was significantly divergent between the two liquisolid 
formulations using different carriers, ie, starch 1500 and 
microcrystalline cellulose. After 60 minutes, more than 
90% of carbamazepine was released from F1 (starch 1500/
ordered mesoporous silica), whereas less than 50% of the 
drug released from F2 (microcrystalline cellulose/ordered 
mesoporous silica) at this time. This clearly indicates that 
the carrier also played an important role in drug release 
from the liquisolid formulation. This is in good agreement 
with previous studies that reported modification of the drug 
release rate from liquisolids using hydroxypropyl methylcel-
lulose (HPMC), Eudragit, and microcrystalline cellulose as 
carriers.35–38 Compared with liquid-filled drug capsules, the 
liquisolid capsules exhibited the advantage of easily con-
trolled drug release using suitable carriers.
The marked difference in carbamazepine release between F1 
and F2 suggests that the carrier formed an intact matrix to con-
trol drug release after granulation. Because starch is hygroscopic 
and swellable in water by nature,39 the starch matrix was rapidly 
destroyed when F1 came into contact with water. Compared 
with starch, microcrystalline   cellulose is slightly hygroscopic 
with a low degree of swelling.40 Drug release from F2 was 
retarded by the matrix of microcrystalline cellulose, resulting 
in a lower rate of drug release than for F1. Because starch and 
microcrystalline cellulose were widely used as carriers in the 
liquisolid, the findings provide direct experimental evidence 
for further study of the liquisolid technique.
Pharmacokinetics
Generally, the bioavailability of carbamazepine, a class II 
drug according to the biopharmaceutic classification system, 
is limited by its poor dissolution, and an increase in   dissolution 
rate would result in an improvement in   bioavailability.41 With 
the improved dissolution properties of liquisolid capsules 
using ordered mesoporous silica (F1), an enhancement of 
pharmacokinetic behavior and bioavailability would be 
expected to be observable in beagle dogs.
The mean carbamazepine plasma concentration-time   profiles 
following oral administration of the commercial tablets and 
the prepared liquisolid capsules (F1) are illustrated in Figure 9, 
and the relevant pharmacokinetic parameters are summarized 
in Table 4. Oral administration of commercial carbamazepine 
tablets resulted in mean peak plasma concentration (Cmax), 
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Table 3 Angle of repose of liquisolid granules prepared with 
various ratios of starch/OMS
Starch 1500:OMS Angle of repose (°)
1:1 53.6
2:1 42.8
4:1 68.9
Abbreviation:OMS, ordered mesoporous silica.
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Figure 9 Mean carbamazepine (CBZ) plasma profiles following a single dose, crossover 
bioavailability study comparing liquisolid capsules with commercial tablets (n = 6).
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mean time to peak plasma concentration (Tmax), and AUC 
values of 669.16 ± 241.43 ng/mL, 69.00 ± 29.24 minutes, and 
66357.26 ± 16549.35 ng ⋅ hour/mL, respectively. Meanwhile, 
following oral administration of liquisolid capsules (F1), 
the corresponding Cmax, Tmax, and AUC values were found 
to be 1031.44 ± 266.69 ng/mL, 60.00 ± 0.00 minutes, and 
117569.41 ± 9390.11 ng ⋅ hour/mL, respectively. Thus, the 
relative bioavailability was calculated as 182.7% (P , 0.05) 
for liquisolid F1 compared with the commercial tablet. The 
in vitro and in vivo studies demonstrated that the liquisolid 
formulation with ordered mesoporous silica improved not only 
the dissolution rate, but also the bioavailability of a poorly 
water-soluble drug.
Moreover, compared with the commercial tablet, 
enhancement of the oral bioavailability of carbamazepine 
via the liquisolid formulation suggested that a lower drug 
dose can be administered using liquisolid capsules to achieve 
similar clinical effects but minimize the associated adverse 
effects.
Conclusion
Ordered mesoporous silica was successfully synthesized as an 
absorbent material for a liquisolid formulation, and exhibited 
an excellent adsorption capacity when compared with con-
ventional silicas. The liquisolid formulation prepared using 
carbamazepine as the model drug, starch as the carrier, and 
ordered mesoporous silica as the coating material showed 
significant improvement of in vitro drug release as compared 
with the commercial fast-release tablet. In vivo testing   further 
demonstrated that the bioavailability of carbamazepine 
from the orally administered liquisolid preparation was 
  significantly enhanced. As a result, ordered mesoporous 
silica as a potentially attractive adsorbent may lead to a new 
approach for development of liquisolid products.
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